Uric Acid: A Metabolic Marker Beyond Gout

Where Uric Acid Comes From

Uric acid is the end product of purine metabolism in humans, produced by xanthine oxidase acting on hypoxanthine and xanthine. Most other mammals convert it further to allantoin using uricase; humans lost that enzyme through mutation, which is why human levels are considerably higher.

Levels reflect production and excretion. Production comes from endogenous purine turnover, dietary purines, and, importantly, fructose metabolism, which consumes ATP and generates AMP that is degraded to uric acid. Excretion is roughly two-thirds renal and one-third intestinal.

The dominant determinant in most people is renal handling rather than intake, which is why dietary purine restriction has a smaller effect than commonly assumed. Genetics affecting renal urate transporters explain much of the between-person variation.

Factors raising it: fructose and alcohol, particularly beer; obesity and insulin resistance, since insulin reduces renal urate excretion; diuretics; impaired kidney function; rapid weight loss and fasting, through ketone competition for excretion; and dehydration.

The Uricase Loss and Why It Might Matter

The loss of uricase in the human lineage is a genuinely interesting piece of evolutionary biology with two competing interpretations.

One reading is that higher uric acid was advantageous. It is an antioxidant in plasma, contributing substantially to total plasma antioxidant capacity, and it raises blood pressure, which may have been useful during periods of low salt availability. The fructose-to-uric-acid pathway has been proposed as a fat-storage mechanism advantageous in seasonal scarcity.

The other reading is that the loss was neutral or mildly deleterious and persisted for other reasons, and that its consequences appear only in a modern environment of abundant fructose and salt.

Either way, the practical inference is the same: a pathway that may have been adaptive under scarcity behaves poorly under abundance, particularly with high fructose intake. That framing connects uric acid to metabolic dysfunction more coherently than a purine-focused view does.

The Associations and the Trial Disappointment

The trial record is the important part. Randomised trials of urate-lowering therapy in chronic kidney disease, aiming to slow progression, have been largely negative. Trials in hypertension have shown small effects at best. Allopurinol trials in cardiovascular outcomes have been mixed and unimpressive.

The likeliest explanation is that uric acid is substantially a marker of the processes it associates with, insulin resistance, adiposity, fructose intake and kidney function, rather than an independent driver. That places it alongside homocysteine as a marker worth interpreting and not worth targeting.

Gout, Which Is a Different Matter

Where uric acid does cause disease directly, the picture is clear and the management is established.

Gout results from monosodium urate crystal deposition when serum urate exceeds saturation. Urate-lowering therapy to a target below saturation prevents attacks and dissolves deposits, and this is one of the better-established target-based relationships in medicine.

Two points are worth knowing because they are frequently misunderstood. Serum urate can be normal during an acute attack, so a normal level does not exclude gout, and identification rests on clinical features and, where needed, joint aspiration showing crystals. And urate-lowering therapy started during an attack, or without prophylaxis, can precipitate further attacks initially, which is why it is introduced carefully.

Dietary advice for gout has shifted. Purine restriction has a modest effect, and the larger dietary contributors are alcohol, particularly beer, and fructose including sugar-sweetened beverages. Weight loss and addressing insulin resistance help. Vitamin C has modest urate-lowering effects, and cherry consumption has some observational support.

Gout is also under-managed. It is associated with cardiovascular and kidney disease, and adherence to urate-lowering therapy is poor, which is a genuine care gap.

What to Do With a Raised Uric Acid

If there is gout or urate stones: that is a clinical situation with established management, and urate-lowering therapy to target is appropriate.

If asymptomatic: the evidence does not support urate-lowering therapy. What it does support is reading the result as a signal about what produced it.

Look at: fructose intake, particularly sugar-sweetened beverages and fruit juice; alcohol intake, particularly beer; body composition and insulin resistance; kidney function; diuretic use; and whether the sample was taken during rapid weight loss or fasting, both of which raise it transiently.

Address those, and the uric acid usually follows. Weight loss, reduced fructose and alcohol, and improved insulin sensitivity all lower it, and they are worth doing regardless.

Interpret alongside HbA1c, fasting insulin, triglycerides, blood pressure, GGT and kidney function. A raised uric acid with a raised triglyceride to HDL ratio, central adiposity and raised liver enzymes is a coherent metabolic picture, and the uric acid is the least important number in it.

Note the low end too. Very low uric acid can reflect specific conditions and reduces plasma antioxidant capacity, and the U-shaped mortality findings in some cohorts suggest it is not simply better lower.

The Recurring Lesson in This Cluster

Uric acid, homocysteine and to some extent ferritin and GGT share a structure worth naming, because recognising it changes how a panel is read.

Each associates with adverse outcomes. Each is mechanistically plausible as a cause. Each is substantially downstream of processes that themselves cause the outcomes, principally insulin resistance, hepatic fat, inflammation and kidney function. And where trials have lowered them directly, the results have been disappointing.

The productive way to read such markers is as indicators pointing toward an upstream process rather than as targets. A raised uric acid is informative because it prompts a look at fructose intake and insulin resistance, and it is not informative as something to lower.

This also explains a common frustration. Someone whose uric acid, homocysteine, GGT and ferritin are all mildly raised does not have four problems. They probably have one, sitting upstream, and addressing it moves all four. That is the argument for reading a panel as a pattern rather than as a list of flags.